[
  {
    "ts": null,
    "headline": "Danaher Corporation (DHR): Maybe It Can Be Great Again, Says Jim Cramer",
    "summary": "We recently published 11 Stocks That Jim Cramer Recently Talked About. Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently discussed. Danaher Corporation (NYSE:DHR) is a stock that Jim Cramer has a bittersweet relationship with. His trust has continued to hold the shares despite the fact that they have lost 11.7% year-to-date. The […]",
    "url": "https://finnhub.io/api/news?id=318d7823f2424b414fc88c5b8b6d64d5f3df2777cac0a43a4846a52a448abad5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753819997,
      "headline": "Danaher Corporation (DHR): Maybe It Can Be Great Again, Says Jim Cramer",
      "id": 136130039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "We recently published 11 Stocks That Jim Cramer Recently Talked About. Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently discussed. Danaher Corporation (NYSE:DHR) is a stock that Jim Cramer has a bittersweet relationship with. His trust has continued to hold the shares despite the fact that they have lost 11.7% year-to-date. The […]",
      "url": "https://finnhub.io/api/news?id=318d7823f2424b414fc88c5b8b6d64d5f3df2777cac0a43a4846a52a448abad5"
    }
  },
  {
    "ts": null,
    "headline": "Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report",
    "summary": "A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market surged past $36 billion in 2024, with projections pointing to continued growth through 2029. The twelfth edition of Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition highlights how decentralization of healthcare, rapid innovation, and consumer-driven demand are reshaping how and where diagnostic tests are performed—from traditional clinical settings to homes, workplaces, and remo",
    "url": "https://finnhub.io/api/news?id=8c0bb388e71af4267aabec993ec2d1c6d8d6206d34825ef164bb96b3fa5159b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753810980,
      "headline": "Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report",
      "id": 136120341,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market surged past $36 billion in 2024, with projections pointing to continued growth through 2029. The twelfth edition of Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition highlights how decentralization of healthcare, rapid innovation, and consumer-driven demand are reshaping how and where diagnostic tests are performed—from traditional clinical settings to homes, workplaces, and remo",
      "url": "https://finnhub.io/api/news?id=8c0bb388e71af4267aabec993ec2d1c6d8d6206d34825ef164bb96b3fa5159b5"
    }
  },
  {
    "ts": null,
    "headline": "Danaher Corp. stock outperforms competitors on strong trading day",
    "summary": "Danaher Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=002d1f407c0a2b5ef33ee03d229d69e7ce35e03a81ce57062f72880ee51d2655",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753806960,
      "headline": "Danaher Corp. stock outperforms competitors on strong trading day",
      "id": 136135921,
      "image": "",
      "related": "DHR",
      "source": "MarketWatch",
      "summary": "Danaher Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=002d1f407c0a2b5ef33ee03d229d69e7ce35e03a81ce57062f72880ee51d2655"
    }
  },
  {
    "ts": null,
    "headline": "Where this large cap portfolio manager see opportunity now",
    "summary": "Looking for a large-cap stock to invest in? In the video above, Macquarie Large Cap Growth Team senior portfolio manager Brad Klapmeyer shares some of the sectors and stocks he's taking a closer look at. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
    "url": "https://finnhub.io/api/news?id=6813b1e68bec9971b382188acae67959c3d6eac336cdf688b39662845c54ce79",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753776000,
      "headline": "Where this large cap portfolio manager see opportunity now",
      "id": 136117134,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Looking for a large-cap stock to invest in? In the video above, Macquarie Large Cap Growth Team senior portfolio manager Brad Klapmeyer shares some of the sectors and stocks he's taking a closer look at. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
      "url": "https://finnhub.io/api/news?id=6813b1e68bec9971b382188acae67959c3d6eac336cdf688b39662845c54ce79"
    }
  },
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Danaher’s Q2 Earnings Call",
    "summary": "Danaher’s second quarter results came in ahead of Wall Street’s revenue and profit expectations, with steady growth in its bioprocessing business and disciplined cost management highlighted by management as key contributors. CEO Rainer Blair pointed to “strong growth in our bioprocessing business, paired with disciplined cost management,” as drivers behind the quarter’s performance. Despite ongoing global trade tensions and a soft environment for academic and government research, the company saw",
    "url": "https://finnhub.io/api/news?id=1acbb12426eba60fd6b594b473c5729103658738513779a93a78b759452ef3da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753767116,
      "headline": "5 Revealing Analyst Questions From Danaher’s Q2 Earnings Call",
      "id": 136130041,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Danaher’s second quarter results came in ahead of Wall Street’s revenue and profit expectations, with steady growth in its bioprocessing business and disciplined cost management highlighted by management as key contributors. CEO Rainer Blair pointed to “strong growth in our bioprocessing business, paired with disciplined cost management,” as drivers behind the quarter’s performance. Despite ongoing global trade tensions and a soft environment for academic and government research, the company saw",
      "url": "https://finnhub.io/api/news?id=1acbb12426eba60fd6b594b473c5729103658738513779a93a78b759452ef3da"
    }
  }
]